Mai-Britt Worm Ørntoft

Mai-Britt Worm Ørntoft

Auto-generated profile, based on publicly available information

Mai-Britt Worm Ørntoft

Affiliations Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, Department of Surgery, Gødstrup Regional Hospital, Gødstrup, Denmark

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JPJillian Phallen
Jillian Phallen
MSMark Sausen
Mark Sausen
VAVilmos Adleff
Vilmos Adleff
ALAlessandro Leal
Alessandro Leal
CHCarolyn Hruban
Carolyn Hruban
VVVictor E. Velculescu
Victor E. Velculescu
Noninvasive liquid biopsy analysis of circulating tumor DNA permits direct detection of early-stage cancers.

10 October 2024 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
NØNadia Øgaard
Nadia Øgaard
SJSarah Østrup Jensen
Sarah Østrup Jensen
MØMai-Britt Worm Ørntoft
Mai-Britt Worm Ørntoft
CDChristina Demuth
Christina Demuth
MRMads Heilskov Rasmussen
Mads Heilskov Rasmussen
CAClaus Lindbjerg Andersen
Claus Lindbjerg Andersen
Background: Multiple initiatives aim to develop circulating tumour DNA (ctDNA) tests for early cancer detection in asymptomatic individuals. The few studies describing ctDNA-testing in both asymptomatic and symptomatic patients report lower ctDNA detection in the asymptomatic patients. Here, we explore if asymptomatic patients differ from symptomatic patients e.g. by including a ‘low-ctDNA-shedding’ and ‘less-aggressive’ subgroup. Methods: ctDNA assessment was performed in two independent cohorts of consecutively recruited patients with asymptomatic colorectal cancer (CRC) (Cohort#1: n = 215, Cohort#2: n = 368) and symptomatic CRC (Cohort#1: n = 117, Cohort#2: n = 722). Results: After adjusting for tumour stage and size, the odds of ctDNA detection was significantly lower in asymptomatic patients compared to symptomatic patients (Cohort#1: OR: 0.4, 95%CI: 0.2–0.8, Cohort#2: OR: 0.7, 95%CI: 0.5–0.9). Further, the recurrence risk was lower in asymptomatic patients (Cohort#1: sHR: 0.6, 95%CI: 0.3–1.2, Cohort#2: sHR: 0.6, 95%CI: 0.4–1.0). Notably, ctDNA-negative asymptomatic patients had the lowest recurrence risk compared to the symptomatic patients (Cohort#1: sHR: 0.2, 95%CI: 0.1–0.6, Cohort#2: sHR: 0.3, 95%CI: 0.2–0.6). Conclusions: Our study suggests that asymptomatic patients are enriched for a ‘low-ctDNA-shedding-low-recurrence-risk’ subgroup. Such insights are needed to guide ctDNA-based early-detection initiatives and should prompt discussions about de-escalation of therapy and follow-up for ctDNA-negative asymptomatic CRC patients.

25 February 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJens Bo Koudahl Conrad
Jens Bo Koudahl Conrad
THTenna Vesterman Henriksen
Tenna Vesterman Henriksen
JNJesper Nors
Jesper Nors
MRMads Heilskov Rasmussen
Mads Heilskov Rasmussen
MØMai-Britt Worm Ørntoft
Mai-Britt Worm Ørntoft
CAClaus Lindbjerg Andersen
Claus Lindbjerg Andersen
Circulating tumor DNA (ctDNA) has high clinical potential in early cancer detection. The renal system and the liver are involved in clearing circulating cell free DNA (cfDNA) from the blood. Recent studies on mice show that inhibiting the liver’s ability to clear cfDNA results in elevated ctDNA levels in blood samples. Emphasizing the need for studies in humans exploring if markers of renal and liver function are associated with cfDNA and ctDNA levels in the blood. The present study investigates if cfDNA level, ctDNA level and ctDNA detection is affected in colorectal cancer (CRC) patients with clinical biomarkers indicative of low renal and liver function. We requisitioned standard laboratory tests of renal and liver function, measured within thirty days of curative intended surgery from 846 stage I-III CRC patients. For each patient, matching preoperative cfDNA and ctDNA data was available. We investigated the correlation between impaired renal and liver function and cfDNA level, ctDNA level, and ctDNA detection. The findings revealed that variation in renal and liver function in stage I-III CRC patients did not affect cfDNA level, ctDNA level, or ctDNA detection and that ctDNA test results remain stable over a wide range of renal and liver biomarker results.

1 July 2018 in Cancer Research
Verified
Journal Article
Closed access
SJSarah Østrup Jensen
Sarah Østrup Jensen
MØMai-Britt Worm Ørntoft
Mai-Britt Worm Ørntoft
NØNadia Øgaard
Nadia Øgaard
HKHelle Kristensen
Helle Kristensen
MRMads Heilskov Rasmussen
Mads Heilskov Rasmussen
CAClaus Lindbjerg Andersen
Claus Lindbjerg Andersen
Background: Screening for colorectal cancer (CRC) using fecal occult blood tests (FOBT) reduces CRC mortality, and many CRC screening programs therefore use FOBT. However, FOBT is not the best approach; first, because population acceptance is low due to unpleasantness of fecal sampling; second, because bowel tumors bleed only intermittently, which limits FOBT sensitivity. Development of a novel blood-based screening approach may alleviate these problems. Objective: This study aims to develop and validate novel blood-based biomarker assays to achieve high patient compliance, sensitivity and specificity. Methods and materials: CRC-specific DNA methylation biomarker candidates were identified using a genome-wide discovery strategy based on >4,000 Illumina 450K DNA methylation arrays. We designed digital droplet PCR assays to detect top biomarker candidates in circulating cell-free DNA (cfDNA) isolated from plasma. Initially, sensitivity and specificity of biomarkers were evaluated in validation cohort 1 consisting of plasma collected from 114 symptomatic CRC patients and 86 colonoscopy-confirmed healthy controls. To ensure comparable technical sensitivities for all assays in all samples, we used a fixed cfDNA input of 4,500 copies per ddPCR reaction. Next, we tested markers in validation cohort 2, a selected cohort of 8 mL plasma collected from participants in the Danish national screening program. This cohort comprised 131 asymptomatic CRCs and 869 controls enriched for comorbidities like adenomas, other cancers, diabetes, arthritis, hypertension, inflammatory bowel disease and arteriosclerosis. Results: Our discovery identified 12 DNA methylation biomarkers. Their performance was evaluated in validation cohort 1, and the three best performing markers showed a sensitivity of 89% at a specificity of 99%, which is superior to FOBT. Sensitivity increased with stage, reaching 65%, 85%, 78% and 83% for stage I-IV, respectively. When evaluated in validation cohort 2, the sensitivity was 51% for CRC samples with an input of at least 4,500 copies of cfDNA, and sensitivity was reduced equally for all disease stages compared with results from validation cohort 1. Sensitivity correlated positively with cfDNA input, and it is therefore critical to collect sufficient plasma volumes to achieve high sensitivities in clinical practice. Finally, specificity was 92.4 % even though we enriched for comorbidities in this cohort, and specificity was 95.7% in controls with a clean colon and no comorbidities. Conclusion: Our systematic biomarker discovery and validation study identified a three-gene DNA methylation panel with superior performance in plasma compared to FOBT. Citation Format: Sarah Østrup Jensen, Mai-Britt Worm Ørntoft, Nadia Øgaard, Helle Kristensen, Mads Heilskov Rasmussen, Jesper Bertram Bramsen, Peter Mouritzen, Mogens Rørbæk, Anne-Sofie Kannerup, Søren Laurberg, Hans Jørgen Nielsen, Claus Lindbjerg Andersen. Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer - A clinical biomarker discovery and validation study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5604.

16 July 2025 in Colorectal Disease
Verified
Journal Article
Open access
RPRupan Paramasivam
Rupan Paramasivam
CJClaudia Jaensch
Claudia Jaensch
AMAnders Husted Madsen
Anders Husted Madsen
MØMai‐Britt Worm Ørntoft
Mai‐Britt Worm Ørntoft
Aim: Successful anastomotic healing is essential in colorectal surgery and depends on adequate microcirculation at the resection site to prevent anastomotic leakage (AL). Traditionally, surgeons subjectively assess this. Laser speckle contrast imaging (LSCI) provides an objective, dye‐free, and non‐contact method for measuring the bowel end microcirculation that could perioperatively support the surgeon's assessment. This study aimed to determine the feasibility of LSCI and evaluate surgeons' subjective opinions on its potential to assist in surgical decision‐making.Method: This feasibility trial was conducted within the IDEAL framework as a non‐interventional multicentre study. Patients undergoing elective right hemicolectomy were included. LSCI measurements were conducted twice perioperatively: before and after anastomosis formation. Surgeons were blinded to all measurements. Postoperatively, LSCI images and a questionnaire were presented to the surgeon asking whether these images, if presented perioperatively, would have influenced the selection of the optimal anastomotic site.Results: High‐quality LSCI measurements were obtained in all 20 patients operated on by 17 different surgeons, with clear and interpretable perfusion images captured without compromising sterility or extending operating time significantly. The device was non‐invasive and added an average of 2 minutes to the total operation time. Fifteen of the 17 surgeons indicated that measures could have influenced surgical decision‐making. In 50% of the cases, the surgeon reported a change in the resection site, by an average of 1.2 cm, based on LSCI images.Conclusion: This study demonstrated that LSCI effectively displays colonic perfusion in real‐time without disrupting the surgical procedure. The potential clinical value of LSCI with additional visual feedback lies in assisting surgeons in selecting the most optimal anastomotic site, thereby potentially improving healing and surgical outcome.

30 September 2023 in Colorectal Disease
Verified
Journal Article
Open access
THTora Rydtun Haug
Tora Rydtun Haug
MØMai‐Britt Worm Ørntoft
Mai‐Britt Worm Ørntoft
DMDanilo Miskovic
Danilo Miskovic
LILene Hjerrild Iversen
Lene Hjerrild Iversen
SJSøren Paaske Johnsen
Søren Paaske Johnsen
AMAnders Husted Madsen
Anders Husted Madsen
Aim: The complete mesocolic excision competency assessment tool (CMECAT) is a novel tool designed to assess technical skills in minimally invasive complete mesocolic excision (CME) surgery. The aim of this study was to assess construct validity and reliability of CMECAT in a clinical context.Method: Colorectal surgeons were asked to submit video recorded laparoscopic CME resections for independent assessment of their technical abilities. The videos were grouped by surgeons' training level, and four established CME experts were recruited as CMECAT assessors. Extended reliability analysis (G‐theory) was applied to describe assessor agreement.Results: A total of 19 videos and 72 assessments were included in the analysis. Overall, technical skills assessed by CMECAT improved with increased training level: the experts scored significantly better than the untrained surgeons (3.3 vs. 2.5 points; p < 0.01). On right‐sided resections, significantly higher scores were reported with increased training level for all categories and sections, while for left‐sided resections, the variance across groups was smaller and significantly higher scores were only reported for oncological safety describing items. Overall, assessor agreement was high (G‐coefficient: 0.81).Conclusion: This study confirms that CMECAT can be applied to video recorded CME cases for technical skill assessment. Further, it can reliably assess technical performance in right sided CME surgery, where construct validity has now been established. More videos are required to evaluate its validity on left colonic CME. In the future, we hope CMECAT can improve feedback during CME training, serve as a tool in certification processes and contribute to distinguishing CME from conventional surgery in future research.